A combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia and its application
The combined use of HDAC inhibitors and PPAR agonists, such as chidamide and sitagliptin, effectively targets AML by inducing ferroptosis, addressing the limitations of current treatments and improving survival rates in AML models.
Patent Information
- Application Number
- CN202210812784.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-07-11
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2042-07-11
AI Technical Summary
Current treatments for acute myeloid leukemia (AML) have limited effectiveness, particularly in older patients, with high relapse rates following allogeneic hematopoietic stem cell transplantation and poor long-term survival rates, and the combination of chidamide and sitagliptin's mechanism of action on AML-related cell lines is unclear.
A combined pharmaceutical composition comprising HDAC inhibitors and PPAR agonists, specifically chidamide and sitagliptin, is used to inhibit AML cell proliferation, induce apoptosis, and inhibit clone formation by inducing ferroptosis in AML cells through the Xc- system, as demonstrated by ferroptosis inhibitor replenishment experiments and cell lipid peroxidation level detection.
The combination of HDAC inhibitors and PPAR agonists significantly inhibits AML cell proliferation, induces apoptosis, and inhibits clone formation, improving survival rates in CDX mouse models by inhibiting the tumor formation process of AML.
Smart Images

Figure CN115068618B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, relates to a new method for preventing or treating acute myeloid leukemia, and relates to a combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia and its application. Background Art
[0002] Acute myeloid leukemia (AML) is a disease with a poor prognosis and rapid development. Its main feature is the abnormal proliferation of poorly differentiated cells, which damages normal hematopoietic function (see Arnone M, et al. Acute Myeloid Leukemia Stem Cells: The Challenges of Phenotypic Heterogeneity. Cancers (Basel). 2020 Dec 12; 12(12): 3742. doi: 10.3390 / cancers12123742. PMID: 33322769; PMCID: PMC7764578). AML patients mainly present with recurrent infections, anemia, easy bleeding and other symptoms related to cell reduction (see De Kouchkovsky, I.; Abdul-Hay, M. Acute myeloid leukemia: A comprehensive review and 2016 update. Blood Cancer J. 2016, 6, e441). Allogeneic hematopoietic stem cell transplantation (HSCT) is one of the treatment strategies for AML. However, nearly 40% of patients who receive allogeneic HSCT relapse, and the survival rate after relapse is poor (see Bejanyan, N. et al., 2015. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol. Blood Marrow Transplant. 21(3), 454–459.). Complete remission (CR) is achieved with common chemotherapy regimens (daunorubicin and cytarabine). As age increases, the treatment outcomes of AML patients continue to decline, and the long-term survival rate of patients is not optimistic (see Juliusson, G. et al., 2009. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 113(18), 4179–4187.). Therefore, research on new strategies for the treatment of AML is urgent.
[0003] Ferroptosis is a new type of cell death discovered in recent years. The process of cell death is usually accompanied by a large amount of iron accumulation and lipid peroxidation. Recent studies have shown that ferroptosis is closely related to the pathophysiological processes of many diseases, such as tumors, nervous system diseases, ischemia-reperfusion injury, kidney damage and blood diseases (see Li J, Cao F, Yin HL, Huang ZJ, Lin ZT, Mao N, Sun B, Wang G. Ferroptosis: past, present and future. Cell Death Dis. 2020 Feb 3; 11(2): 88. doi: 10.1038 / s41419-020-2298-2. PMID: 32015325; PMCID: PMC6997353.). Research by David T. Scadden et al. showed that inhibition of aldehyde dehydrogenase 3a2 (Aldh3a2) can induce ferroptosis in AML cells, providing a new target for the treatment of AML (see Yusuf RZ, Saez B, et al.. Aldehyde dehydrogenase 3a2 protects AML cells from oxidative death and the synthetic lethality of ferroptosis inducers. Blood. 2020 Sep 10; 136(11): 1303-1316. doi: 10.1182 / blood.2019001808. PMID: 32458004; PMCID: PMC7483435.).
[0004] Chidamide is a new molecular entity drug exclusively discovered by Shenzhen Chipscreen Biopharmaceuticals and protected by global patents. It is the first original chemical new drug approved for marketing in my country and the world's first subtype-selective histone deacetylase (HDAC) oral inhibitor. It belongs to the class of epigenetic regulators with novel mechanisms. Chiglitazar Sodium is a new generation of insulin sensitizer new molecular entity independently designed, synthesized, screened and developed by Shenzhen Chipscreen Biopharmaceuticals, mainly used to treat type 2 diabetes. It has also become the world's first PPAR full agonist approved for the treatment of type 2 diabetes. Research by Ping-Ping Li et al. showed that chiglitazar can improve insulin resistance and dyslipidemia in obese rats (see Li PP, Shan S, Chen YT, Ning ZQ, Sun SJ, Liu Q, Lu XP, Xie MZ, Shen ZF. The PPARalpha / gammadual agonist chiglitazar improves insulin resistance and dyslipidemia in MS Gobese rats. Br J Pharmacol. 2006 Jul; 148(5): 610-8. doi: 10.1038 / sj.bjp.0706745. Epub 2006 Jun 5. PMID: 16751799; PMCID: PMC1751868.).
[0005] However, it is still unclear whether the combination of chidamide and sitagliptin can be used to treat AML and its mechanism of action on AML-related cell lines. Summary of the invention
[0006] In view of the deficiencies of the prior art, the purpose of the present invention is to provide a new method for preventing or treating acute myeloid leukemia, and to provide a combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia and its application.
[0007] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:
[0008] In a first aspect, the present invention provides a combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia, wherein the combined pharmaceutical composition comprises an HDAC inhibitor and a PPAR agonist.
[0009] The combined pharmaceutical composition involved in the present invention creatively combines HDAC inhibitors and PPAR agonists as a drug for preventing or treating acute myeloid leukemia. The present invention has found that the combination of PPAR agonists and HDAC inhibitors has a more significant effect of inhibiting AML cell proliferation, inducing AML cell apoptosis, and inhibiting AML cell clone formation ability than single PPAR agonists or HDAC inhibitors. The present invention also proves that the combination of PPAR agonists and HDAC inhibitors can induce ferroptosis in AML cells through ferroptosis inhibitor replenishment experiments and cell lipid peroxidation level detection; and proves that the combination of PPAR agonists and HDAC inhibitors can inhibit Xc related to ferroptosis in AML cells through cell GSH level detection, RT-PCR and WB experiments. - system; finally, the CDX mouse model was used to prove that the PPAR agonist combined with the HDAC inhibitor can inhibit the tumorigenesis process of mouse AML and improve the survival rate of mice. The schematic diagram of its mechanism of action in inhibiting the occurrence and development of AML is shown in the figure Figure 1 shown.
[0010] The present invention provides an effective drug combination strategy for the treatment of acute myeloid leukemia, which has very significant significance.
[0011] Preferably, the HDAC inhibitor comprises: Entinostat, Vorinostat, Panobinostat, Mocetinostat, Belinostat, Pracinostat, Romidepsin, Chidamide, or any one or a combination of at least two of the pharmaceutically acceptable salts, isomers, solvates, and metabolites of the above compounds;
[0012] Preferably, the HDAC inhibitor is chidamide or any one or a combination of at least two of its pharmaceutically acceptable salts, isomers, solvates, metabolites.
[0013] Preferably, the PPAR agonist includes: Chiglitazar, Fenofibrate, Gemfibrozil, Fenofibric acid, Flufenamic acid, Ibuprofen, Bezafibrate, Indomethacin, Rosiglitazone, Ciprofibrate, Valproicacid, Dexibuprofen, Amiodarone, Prasterone, alpha-Linolenic acid, PPM-204, Clinofibrate, Myrrh, Palmitic Acid, Fenoprofen, Lauric Acid, Stearic Acid. acid), Clofibrate, Doconexent, Oleic Acid, Troglitazone, Omega-3 fatty acids, Icosapent, Myristic acid, Arachidonic Acid, Isoflavone, Aleglitazar, Reglitazar, Elafibranor, Muraglitazar, Ertiprotafib, Phthalic Acid, Ragaglitazar, Tesaglitazar, GW-590735, Leukotriene B4, Caprylic Acid acid), GW501516 (Cardarine), resveratrol (Resveratrol), N, N-bis (3- (D-gluconamido) propyl) deoxycholamide (N, N-Bis (3- (D-gluconamido) propyl) deoxycholamide) or any one or a combination of at least two of the above compounds in a pharmaceutically acceptable salt, isomer, solvate, metabolite.
[0014] Preferably, the PPAR agonist is cigligliptin or any one of its pharmaceutically acceptable salts, isomers, solvates, metabolites, or a combination of at least two thereof.
[0015] Preferably, the pharmaceutically acceptable salt includes any one of an alkali metal salt, an alkaline earth metal salt, an ammonium salt or a quaternary ammonium salt, preferably an alkali metal salt, and more preferably a sodium salt or a potassium salt.
[0016] Preferably, the PPAR agonist is sitagliptin sodium, sitagliptin potassium or the levorotatory isomer thereof.
[0017] Preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
[0018] Preferably, the combination pharmaceutical composition of the present invention can be administered alone or in combination with excipients to make an appropriate dosage form for administration. The pharmaceutically acceptable excipients include any one or a combination of at least two of carriers, diluents, excipients, fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, antibacterial agents or buffers.
[0019] The combination of at least two agents, for example, a combination of a diluent and an excipient, a combination of an emulsifier and a solubilizer, a combination of a filler, an adhesive and a wetting agent, etc., any other combination can be selected and will not be described in detail here.
[0020] Preferably, the combination pharmaceutical composition is a single compound preparation or a combination of two separate preparations.
[0021] Preferably, the combined pharmaceutical composition is a combination of two separate preparations, and the two separate preparations are administered simultaneously or sequentially.
[0022] The combination pharmaceutical composition may be in the form of a single compound preparation or a combination of two separate preparations; when it is a combination of two separate preparations, the administration method may be simultaneous administration, cross administration or sequential administration.
[0023] Preferably, the preparation is any pharmaceutically acceptable dosage form, such as tablets, powders, suspensions, granules, capsules, solutions, enemas, emulsions, etc.
[0024] Preferably, the unit dose of the HDAC inhibitor is 1-100 mg, preferably 5-80 mg; further, the unit dose of chidamide or its pharmaceutically acceptable salt, isomer, solvate, metabolite is 5-100 mg, preferably 5-60 mg.
[0025] Preferably, the unit dose of the PPAR agonist is 1-50 mg, preferably 4-25 mg; further, the unit dose of sitagliptin sodium is 5-50 mg, preferably 10-20 mg.
[0026] In a second aspect, the present invention provides a use of the combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia according to the first aspect in the preparation of a drug for preventing, ameliorating or treating acute myeloid leukemia.
[0027] In a third aspect, the present invention provides a use of the combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia according to the first aspect in the preparation of a proliferation inhibitor, apoptosis promoter or clone formation inhibitor of acute myeloid leukemia cells.
[0028] Preferably, the acute myeloid leukemia cells are cell lines that induce acute myeloid leukemia.
[0029] Preferably, the cell line comprises KG-1α cells and / or Kasumi-1 cells.
[0030] In a fourth aspect, the present invention provides a combination pharmaceutical composition for preventing and / or treating acute myeloid leukemia according to the first aspect for use in the preparation of a proliferation inhibitor, apoptosis promoter or clone formation inhibitor of acute myeloid leukemia cells for non-diagnostic and / or therapeutic purposes.
[0031] According to the research results of the present invention, the combined pharmaceutical composition has the effect of significantly inhibiting the proliferation of acute myeloid leukemia cells, significantly inducing apoptosis of acute myeloid leukemia cells, and significantly inhibiting the cloning of acute myeloid leukemia cells. Therefore, the results indicate that the combined pharmaceutical composition can be used as an acute myeloid leukemia cell proliferation inhibitor, apoptosis promoter or cloning inhibitor for non-diagnostic and / or therapeutic purposes, and can be used in the field of scientific research, such as studying more acute myeloid leukemia cell growth, apoptosis, cloning and metabolic mechanisms or behaviors, screening drugs for treating acute myeloid leukemia, etc.
[0032] In a fifth aspect, the present invention provides a combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia according to the first aspect in the preparation of Xc related to ferroptosis. - Application of inhibitors in the system.
[0033] Preferably, the Xc associated with ferroptosis - Xc system is associated with ferroptosis in AML - system.
[0034] In a sixth aspect, the present invention provides a combination pharmaceutical composition for preventing and / or treating acute myeloid leukemia according to the first aspect for the preparation of a ferroptosis-related Xc - Application of inhibitors in the system.
[0035] According to the research results of the present invention, the combined pharmaceutical composition has the effect of significantly inhibiting Xc2+ associated with ferroptosis. - Therefore, the results show that the combined pharmaceutical composition can be used as a non-diagnostic and / or therapeutic Xc related to ferroptosis - System inhibitors, used in scientific research.
[0036] In a seventh aspect, the present invention provides a use of the combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia according to the first aspect in the preparation of an HDAC3 expression inhibitor or a SLC7A11 expression inhibitor.
[0037] Preferably, the HDAC3 is HDAC3 in AML; and the SLC7A11 is SLC7A11 in AML.
[0038] In an eighth aspect, the present invention provides a use of the combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia according to the first aspect in the preparation of an HDAC3 expression inhibitor or a SLC7A11 expression inhibitor for non-diagnostic and / or therapeutic purposes.
[0039] According to the research results of the present invention, the combined pharmaceutical composition has the effect of significantly inhibiting the expression of HDAC3 or SLC7A11. Therefore, the results indicate that the combined pharmaceutical composition can be used as an HDAC3 expression inhibitor or SLC7A11 expression inhibitor for non-diagnostic and / or therapeutic purposes in the field of scientific research, such as studying more HDAC3 or SLC7A11 expression behaviors.
[0040] Compared with the prior art, the present invention has the following beneficial effects:
[0041] The combined pharmaceutical composition involved in the present invention creatively combines HDAC inhibitors and PPAR agonists as a drug for preventing or treating acute myeloid leukemia. The present invention has found that the combination of PPAR agonists and HDAC inhibitors has a more significant effect of inhibiting AML cell proliferation, inducing AML cell apoptosis, and inhibiting AML cell clone formation ability than single PPAR agonists or HDAC inhibitors. The present invention also proves that the combination of PPAR agonists and HDAC inhibitors can induce ferroptosis in AML cells through ferroptosis inhibitor replenishment experiments and cell lipid peroxidation level detection; and proves that the combination of PPAR agonists and HDAC inhibitors can inhibit Xc related to ferroptosis in AML cells through cell GSH level detection, RT-PCR and WB experiments. - system; finally, the CDX mouse model was used to prove that the PPAR agonist combined with the HDAC inhibitor can inhibit the tumor formation process of mouse AML and improve the survival rate of mice. The present invention provides an effective drug combination strategy for the treatment of acute myeloid leukemia, which has a very significant significance.
[0042] The schematic diagram of the mechanism of action of the combined pharmaceutical composition of the present invention in inhibiting the occurrence and development of AML is as follows: Figure 1 As shown: Chidamide combined with sitagliptin can inhibit the HDAC3 / SLC7A11 pathway in AML cell lines KG-1α and Kasumi-1, thereby inhibiting the Xc11 signaling pathway associated with ferroptosis. - system, inducing cell ferroptosis and ultimately inhibiting the occurrence and development of AML. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] Figure 1 It is a schematic diagram of the mechanism of action of the combined pharmaceutical composition of the present invention in inhibiting the occurrence and development of AML;
[0044] Figure 2A This is the result of the cell proliferation inhibition rate of KG-1α cells treated with chidamide combined with sitagliptin for 24 hours;
[0045] Figure 2B This is the result of the cell proliferation inhibition rate of Kasumi-1 cells treated with chidamide combined with sitagliptin for 24 hours;
[0046] Figure 3A This is the result of flow cytometry detection of cell apoptosis level in KG-1α cells after treatment with chidamide combined with sitagliptin for 24 hours;
[0047] Figure 3B This is the statistical result of apoptosis rate of KG-1α cells;
[0048] Figure 3CThis is the result of flow cytometry detection of cell apoptosis in Kasumi-1 cells after treatment with chidamide combined with sitagliptin for 24 hours;
[0049] Figure 3D This is the statistical result of apoptosis rate of Kasumi-1 cells;
[0050] Figure 4A This is the result of cell clone formation after KG-1α cells were treated with chidamide combined with sitagliptin for 24 hours;
[0051] Figure 4B This is a statistical diagram of the clone formation results of KG-1α cells;
[0052] Figure 4C This is the result of cell clone formation after Kasumi-1 cells were treated with chidamide combined with sitagliptin for 24 hours;
[0053] Figure 4D This is a statistical diagram of the clone formation results of Kasumi-1 cells;
[0054] Figure 5A This is a graph showing that the ferroptosis inhibitor Ferrostatin-1 (Fer-1) can compensate for the inhibitory effect of the combination of chidamide and sitagliptin on the proliferation level of KG-1α cells;
[0055] Figure 5B This is a result diagram showing that the ferroptosis inhibitor Ferrostatin-1 (Fer-1) can compensate for the inhibitory effect of the combination of chidamide and sitagliptin on the proliferation level of Kasumi-1 cells;
[0056] Figure 5C This is a statistical graph showing the results of lipid peroxidation levels in KG-1α cells treated with chidamide combined with sitagliptin for 24 hours;
[0057] Figure 5D This is a statistical graph showing the results of lipid peroxidation levels in Kasumi-1 cells treated with chidamide combined with sitagliptin for 24 hours;
[0058] Fig. 6A This is a statistical chart showing the level of reduced glutathione (GSH) generated in KG-1α cells after 24 hours of treatment with chidamide combined with sitagliptin;
[0059] Figure 6B This is a statistical graph showing the level of reduced glutathione (GSH) generated in Kasumi-1 cells after treatment with chidamide combined with sitagliptin for 24 hours;
[0060] Figure 6CThis is a statistical graph showing the expression of SLC7A11 mRNA levels in KG-1α cells after treatment with chidamide combined with sitagliptin for 24 hours;
[0061] Fig.6D This is a statistical graph showing the expression of SLC7A11 mRNA levels in Kasumi-1 cells after treatment with chidamide combined with sitagliptin for 24 hours;
[0062] Fig. 6E This is the Western blot result of the protein expression levels of HDAC3 and SLC7A11 in KG-1α cells after treatment with chidamide combined with sitagliptin for 24 hours;
[0063] Fig. 6F The Western blot results of HDAC3 and SLC7A11 protein expression levels in Kasumi-1 cells after treatment with chidamide combined with sitagliptin for 24 hours;
[0064] Fig. 7A In vivo imaging images of CDX mouse models on the 7th and 14th days after treatment with chidamide combined with sitagliptin;
[0065] Figure 7B This is a statistical chart of the survival rate of mice in the CDX mouse model after treatment with chidamide combined with sitagliptin. DETAILED DESCRIPTION
[0066] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.
[0067] The process, conditions, reagents, experimental methods, etc. for implementing the present invention, except for the contents specifically mentioned below, are all common knowledge and common common sense in the art, and the present invention has no particular restrictions. The experimental methods without specifying specific conditions in the embodiments are usually carried out under conventional conditions or under conditions recommended by the manufacturer.
[0068] Unless otherwise specified, all technical terms and scientific terms used in this specification have the same meaning as those generally understood by those skilled in the art to which the present invention belongs. However, in case of any conflict, the present specification including the definitions shall prevail.
[0069] The drugs Chidamide and Chiglitazar involved in the following examples are both provided by Shenzhen ChipScreen Biotechnology Co., Ltd.
[0070] AML cell lines (including KG1α and Kasumi-1) were provided by the Institute of Hematology, Xiamen University School of Medicine.
[0071] Example 1
[0072] Inhibitory effect of combined drug composition on proliferation of AML cell lines
[0073] The operation method is: take the quantity as 1×10 4 AML cell lines (including KG1α and Kasumi-1 cell lines) in the logarithmic growth phase were inoculated in 96-well plates, and the chidamide monotherapy group, sitagliptin sodium monotherapy group, chidamide and sitagliptin sodium combination group, and control group were set up;
[0074] The single-drug concentrations of chidamide in the experimental group cells were 1 μM, 2 μM, 4 μM and 8 μM, respectively, and the corresponding single-drug concentrations of sitagliptin were 4 μM, 8 μM, 16 μM and 32 μM, respectively. The concentrations of the combination group of chidamide and sitagliptin were 1 μM+4 μM, 2 μM+8 μM, 4 μM+16 μM, 8 μM+32 μM, respectively (the former was chidamide and the latter was sitagliptin), wherein the cells in the control group were treated with the same volume of DMSO; the corresponding volume of drug or DMSO was gently shaken and mixed with the cells in the above-mentioned 96-well cell culture plate, and then cultured in a cell culture incubator (Thermo) for 24 hours, and the cell proliferation level was detected using a CCK8 kit (MCE, Shanghai).
[0075] The results of cell proliferation levels in each group are shown in Figure 2A (KG1α) and Figure 2B (Kasumi-1)
[0076] Combined with the above results, it can be seen that compared with single drug, the combination of cedabenbine and sitagliptin showed a more significant inhibitory effect on the proliferation levels of AML cell lines KG-1α and Kasumi-1.
[0077] Example 2
[0078] Apoptosis-inducing effect of combined drug combination on AML cell line
[0079] The operation method is: take the quantity as 2×10 5 AML cell lines (including KG1α and Kasumi-1 cell lines) in the logarithmic growth phase were inoculated in 24-well plates, and the chidamide monotherapy group, sitagliptin sodium monotherapy group, chidamide and sitagliptin sodium combination group, and control group were set up;
[0080] The single-drug concentrations of chidamide in the experimental group cells were 1 μM, 2 μM, 4 μM and 8 μM, respectively, and the corresponding single-drug concentrations of sitagliptin were 4 μM, 8 μM, 16 μM and 32 μM, respectively. The concentrations of the combination group of chidamide and sitagliptin were 1 μM+4 μM, 2 μM+8 μM, 4 μM+16 μM, 8 μM+32 μM, respectively (the former was chidamide, and the latter was sitagliptin), wherein the cells in the control group were treated with the same volume of DMSO; the corresponding volume of drug or DMSO was gently shaken and mixed with the cells in the above-mentioned 24-well cell culture plate, and then cultured in a cell culture incubator for 24 hours, and then centrifuged at 4°C, 300g for 5 minutes to collect the cells, washed once with PBS, and then the cell apoptosis level was detected by AnnexinV / PI (Thermofisher, USA) flow staining and the cell apoptosis rate was calculated.
[0081] Figure 3A and Figure 3B They are flow cytometry results of cell apoptosis level and apoptosis rate statistics of KG-1α cells treated with chidamide combined with sitagliptin for 24 hours; Figure 3C and Figure 3D These are the flow cytometry results of cell apoptosis level and apoptosis rate statistics of Kasumi-1 cells treated with chidamide combined with sitagliptin for 24 hours.
[0082] From the above results, it can be seen that compared with single drug, the combination of cedabenbine and sitagliptin can more significantly induce the apoptosis level of AML cell lines KG-1α and Kasumi-1.
[0083] Example 3
[0084] Inhibitory effect of combined drug composition on clone formation of AML cell line
[0085] The operation method is: take 2×10 5 AML cell lines KG-1α and Kasumi-1 in the logarithmic growth phase were seeded in 24-well cell culture plates;
[0086] A single-drug group of chidamide, a single-drug group of sitagliptin, a combination group of chidamide and sitagliptin, and a control group were set up; the single-drug concentration of chidamide in the experimental group was 4 μM, and the corresponding single-drug concentration of sitagliptin was 16 μM, and the concentration of the combination group of chidamide and sitagliptin was 4 μM+16 μM (the former was chidamide, and the latter was sitagliptin), and the cells in the control group were treated with the same volume of DMSO; the corresponding volume of drug or DMSO was gently shaken and mixed with the cells in the above 24-well cell culture plate, and after culturing in a cell culture incubator for 24 hours, 500 cells were taken out by live cell counting to further detect the cell cloning ability by soft agar experiment (Lablead, Beijing).
[0087] Figure 4A and Figure 4B This is a graph showing the cell clone formation and statistical results of KG-1α cells after treatment with chidamide combined with sitagliptin; Figure 4C and Figure 4D These are the cell clone formation results and statistical results of Kasumi-1 cells after treatment with chidamide combined with sitagliptin.
[0088] The results showed that compared with single drug, the combination of cedabenbine and sitagliptin significantly inhibited the cell clone formation ability of AML cell lines KG-1α and Kasumi-1.
[0089] Example 4
[0090] Chidamide combined with sitagliptin induces ferroptosis in AML cell lines
[0091] The operation method is: first, take 1×10 4 AML cell lines KG-1α and Kasumi-1 in the logarithmic growth phase were seeded in 96-well cell culture plates;
[0092] The cells were divided into a single-agent chidamide group, a single-agent sitagliptin group, a combined chidamide and sitagliptin group, a ferroptosis inhibitor group, a combined chidamide and sitagliptin group and a ferroptosis inhibitor group, and a control group. The chidamide concentration of the experimental group was 4 μM, the corresponding sitagliptin concentration was 16 μM, the ferroptosis inhibitor Ferrostatin-1 (Fer-1) (Topscience, Shanghai) concentration was 2 μM, and the concentration of the combined chidamide and sitagliptin group was 4 μM + 16 μM. (the former is chidamide, and the latter is sitagliptin), the concentrations of the chidamide and sitagliptin combination group and the ferroptosis inhibitor group are 4μM+16μM+2μM (the former is chidamide, the middle is sitagliptin, and the latter is ferroptosis inhibitor), and the cells in the control group were treated with the same volume of DMSO; the corresponding volume of drug or DMSO was gently shaken and mixed with the cells in the above 96-well cell culture plate, and the cell viability was detected using a CCK8 kit (MCE, Shanghai) after culturing in a cell culture incubator for 24 hours.
[0093] The results are as follows Figure 5A and Figure 5B As shown, the ferroptosis inhibitor Ferrostatin-1 (Fer-1) can complement the inhibitory effect of chidamide combined with sitagliptin on the proliferation levels of AML cell lines KG-1α and Kasumi-1 cells.
[0094] Secondly, take 2×10 5AML cell lines KG-1α and Kasumi-1 in the logarithmic growth phase were seeded in 24-well cell culture plates;
[0095] A single-drug group of chidamide, a single-drug group of sitagliptin, a combined group of chidamide and sitagliptin, and a control group were set; the single-drug concentration of chidamide in the experimental group was 4 μM, and the corresponding single-drug concentration of sitagliptin was 16 μM, and the concentration of the combined group of chidamide and sitagliptin was 4 μM+16 μM (the former was chidamide, and the latter was sitagliptin), wherein the cells in the control group were treated with the same volume of DMSO; the corresponding volume of drug or DMSO was lightly shaken and mixed with the cells in the above 24-well cell culture plate, cultured in a cell culture incubator for 24 h, stained with 10 μM BODIPY 581 / 591 C11 (ABclonal, Wuhan) in a cell culture incubator for 1 h, and the cells were collected by centrifugation at 4°C and 300 g for 5 min, and the lipid peroxidation levels of KG-1α and Kasumi-1 cells were detected by cell flow cytometry after resuspending in PBS;
[0096] The results are as follows Figure 5C and Figure 5D As shown, it was shown that the combination of cedabenbine and sitagliptin enhanced the lipid peroxidation level of AML cell lines KG-1α and Kasumi-1.
[0097] In conclusion, chidamide combined with sitagliptin induces ferroptosis in AML cell lines KG-1α and Kasumi-1.
[0098] Example 5
[0099] Chidamide combined with sitagliptin inhibits ferroptosis-related Xc in AML cell lines - system
[0100] The operation method is: first, take 2×10 5 AML cell lines KG-1α and Kasumi-1 in the logarithmic growth phase were seeded in 24-well cell culture plates;
[0101] A single-drug group of chidamide, a single-drug group of sitagliptin, a combined group of chidamide and sitagliptin, and a control group were set; the single-drug concentration of chidamide in the experimental group was 4 μM, and the corresponding single-drug concentration of sitagliptin was 16 μM, and the concentration of the combined group of chidamide and sitagliptin was 4 μM+16 μM (the former was chidamide, and the latter was sitagliptin), wherein the cells in the control group were treated with the same volume of DMSO; the corresponding volume of drug or DMSO was gently shaken and mixed with the cells in the above-mentioned 24-well cell culture plate, cultured in a cell culture incubator for 24 h, centrifuged at 4°C, 300 g for 5 min to collect the cells, washed once with PBS, and finally the GSH (reduced glutathione) detection kit (ABclonal, Wuhan) was used to detect the GSH production level of KG-1α and Kasumi-1 cells;
[0102] The results are as follows Fig. 6A and Figure 6B As shown, it was shown that the combination of cedabenbine and sitagliptin inhibited the GSH production level of AML cell lines KG-1α and Kasumi-1.
[0103] Secondly, take 1×10 6 AML cell lines KG-1α and Kasumi-1 in the logarithmic growth phase were inoculated in 6-cm cell culture dishes;
[0104] A single-drug group of chidamide, a single-drug group of sitagliptin, a combined group of chidamide and sitagliptin, and a control group were set; the single-drug concentration of chidamide in the experimental group was 2 μM, and the corresponding single-drug concentration of sitagliptin was 8 μM; the concentration of the combined group of chidamide and sitagliptin was 2 μM+8 μM (the former was chidamide, and the latter was sitagliptin), and the cells in the control group were treated with the same volume of DMSO; the corresponding volume of drug or DMSO was gently shaken and mixed with the cells in the above 6 cm cell culture dish, cultured in a cell culture incubator for 24 h, centrifuged at 4°C, 300g for 5 min to collect the cells, and half of the cells were lysed on ice for 1 h with 200 μL of RIPA lysis buffer (Thermo, USA), and the total protein was extracted for Western blot to detect the protein expression levels of HDAC3 and SLC7A11;
[0105] The other half of the cells were added with 500 μL Trizol reagent (Transgen, Beijing) to extract total RNA, which was further reverse transcribed using a reverse transcription kit (Transgen, Beijing) to obtain total cDNA. Finally, primers were designed for RT-PCR to detect the expression of the SLC7A11 gene at the mRNA level.
[0106] Figure 6C and Fig.6DThe expression of SLC7A11 gene at the mRNA level in AML cell lines KG-1α and Kasumi-1 indicates that the combination of chidamide and sitagliptin inhibits the expression of SLC7A11 gene at the mRNA level;
[0107] Fig. 6E and Fig. 6F The results of Western blot showed that the combination of chidamide and sitagliptin inhibited the protein expression of HDAC3 and SLC7A11 in AML cell lines KG-1α and Kasumi-1;
[0108] In conclusion, the combination of chidamide and sitagliptin induces ferroptosis-related Xc in AML cell lines KG-1α and Kasumi-1. - system.
[0109] Example 6
[0110] The tumorigenesis process of AML in vivo by combining chidamide with sitagliptin
[0111] The specific operation method is as follows:
[0112] (1) A control group, a chidamide monotherapy group, a sitagliptin sodium monotherapy group, and a chidamide and sitagliptin sodium combination group were set up, wherein chidamide and sitagliptin sodium were prepared into a suspension with 0.5% sodium carboxymethylcellulose.
[0113] (2) Construction of CDX mouse model
[0114] The PLV-luciferase-GFP plasmid (provided by the Institute of Hematology, Xiamen University School of Medicine) was transfected into the KG-1α cell line by lentiviral stable transfection method, and KG-1α cells stably expressing luciferase were constructed. 6 luciferase-GFP-KG-1α in the logarithmic growth phase was injected into NOD-Prkdc cells via tail vein - / - IL - / - The CDX mouse model was established by forming tumors in NSG mice.
[0115] (3) About 14 days after injection, the drug was administered at a dose of 10 mg / kg / day for cedabenamide and 10 mg / kg / day for sitagliptin. The drug was administered for 14 consecutive days. The tumor progression of mice was detected by a live imaging system, and the day of drug administration was taken as day 0 to calculate the experimental results and the survival rate of mice. NSG mice were purchased from the Experimental Animal Center of Xiamen University and were raised by the Experimental Animal Center.
[0116] The results are as follows Fig. 7A and Figure 7BAs shown, the combination of cedabenbine and sitagliptin inhibited the tumor formation process of the CDX model and significantly improved the survival rate of the CDX model.
[0117] The present invention illustrates a combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia and its application through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.
[0118] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.
[0119] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.
Claims
1. Use of a combined pharmaceutical composition for treating acute myeloid leukemia in the preparation of a drug for improving or treating acute myeloid leukemia, characterized in that: The combined pharmaceutical composition is an HDAC inhibitor and a PPAR agonist; The HDAC inhibitor is chidamide; The PPAR agonist is sitagliptin; The unit dose of chidamide is 5-100 mg; The unit dose of sitagliptin sodium is 5-50 mg.
2. The use according to claim 1, characterized in that: The drug also includes pharmaceutically acceptable excipients.
3. The use according to claim 1, characterized in that: The combined pharmaceutical composition is a single compound preparation or a combination of two separate preparations.
4. The use according to claim 3, characterized in that: The combined pharmaceutical composition is a combination of two separate preparations, and the two separate preparations are administered simultaneously or sequentially.
5. The use according to claim 3, characterized in that: The preparation is in any pharmaceutically acceptable dosage form.
Citation Information
Patent Citations
Battery separator
JP1995006745A
Combined pharmaceutical composition for treating acute myelogenous leukemia and application thereof
CN113577070A
Application of PPAR agonist in preparation of medicine for treating acute myeloid leukemia (AML)
CN113813387A
Cancer Therapy And Medicaments Therefor
US20090105343A1
PPAR-gamma ACTIVATORS, HDAC INHIBITORS AND THEIR THERAPEUTICAL USAGES
US20190298673A1
